MIRA INFORM REPORT

 

 

Report Date :

19.03.2012

 

IDENTIFICATION DETAILS

 

Name :

SRIKEM LABORATORIES PRIVATE LIMITED

 

 

Registered Office :

Flat No.8, 2nd Floor, Laxmi Bhavan, Plot No.172-A, Jain Society, Sion (West), Mumbai – 400 022, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2011

 

 

Date of Incorporation :

30.08.1996

 

 

Com. Reg. No.:

11-102255

 

 

Capital Investment / Paid-up Capital :

Rs.2.000 Millions

 

 

CIN No.:

[Company Identification No.]

U24110MH1996PTC102255

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

MUMS27197C

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Manufacturer of Bulk Drug and Pharmaceutical Products.

 

 

No. of Employees :

Not Available

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba (48)

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 192000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

Usually Correct

 

 

Litigation :

Clear

 

 

Comments :

Subject is an established company having satisfactory track. Trade relations are fair. Business is active. Payments are reported to be usually correct and as per commitments.

 

The company can be considered for business dealings at usual trade terms and conditions.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – September 30, 2011

 

Country Name

Previous Rating

(30.06.2011)

Current Rating

(30.09.2011)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

 

 

 

 

 

 

 

 

 

 

 

LOCATIONS

 

Registered Office :

Flat No.8, 2nd Floor, Laxmi Bhavan, Plot No.172-A, Jain Society, Sion (West), Mumbai – 400 022, Maharashtra, India

Tel. No.:

91-22-24041114/ 65167208

Fax No.:

91-22-24045896

E-Mail :

srikem@vsnl.com

info@srikem.com

srinivasan.srikem@gmail.com

Website :

http://www.srikem.com

http://www.srikem.org

 

 

Factory :

Plot No. 17/22, 17/24 and 17/13, MIDC Taloja, Navi Mumbai – 410 208, Maharashtra, India

Tel. No.:

91-22-27402408/ 27410459/ 65108580/ 65108581

Fax No.:

91-22-27402631/ 24045896

E-Mail :

srikem@hotmail.com

srikem@rediffmail.com

info@srikem.com

srikem@vsnl.com

 

 

DIRECTORS

 

As on 30.09.2011

 

Name :

Mr. Srinivasan Subramanyam

Designation :

Chairman cum Managing Director

Address :

8/172A, 2nd Floor, Laxmi Bhuvan, Sion (West), Mumbai – 400 022, Maharashtra, India

Date of Birth/Age :

06.01.1956

Date of Appointment :

30.08.1996

DIN No.:

00914112

 

 

Name :

Mr. Ramachandran Venkatrama Kuttuchery

Designation :

Director

Address :

2/59, United India Building, Sion (West), Mumbai – 400 022, Maharashtra, India

Date of Birth/Age :

20.12.1925

Date of Appointment :

30.08.1996

DIN No.:

02412017

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 30.09.2011

 

Names of Shareholders

 

No. of Shares

Srinivasan Subramanyam

 

159900

K.V. Ramachandran

 

100

Chitra Shankar

 

30000

Mythili Srinivasan

 

10000

Total

 

200000

 

Equity Share Break up (Percentage of Total Equity)

 

As on 30.09.2011

 

Category

Percentage

Directors or relatives of Directors

100.00

Total

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer of Bulk Drug and Pharmaceutical Products.

 

 

Products :

  • Bulk Drug
  • Pharmaceutical Products

 

 

GENERAL INFORMATION

 

No. of Employees :

Not Available

 

 

Bankers :

  • Oriental Bank of Commerce, Meendeep, Ground Floor, 175. Gujarat Society, Sion (West), Mumbai – 400022, Maharashtra, India
  • Janakalyan Sahakari Bank Limited, 140, Vivek Darshan, Sindhi Society, Chembur, Mumbai – 400 071, Maharashtra, India
  • State Bank of India

 

 

Facilities :

Secured Loan

As on

31.03.2011

(Rs. in

Millions)

As on

31.03.2010

(Rs. in

Millions)

Oriental Bank of Commerce – Cash Credit A/c

(Secured against book debts, stock and personal guarantee of Directors)

8.555

3.873

Export Advances

(Packing credit and post shipment advances)

10.785

8.145

 Oriental Bank of Commerce – Term Loan

(Secured by land and building plant and machinery, and personal guarantee of Directors)

10.732

17.749

Total

30.072

29.767

 

 

Unsecured Loan

As on

31.03.2011

(Rs. in

Millions)

As on

31.03.2010

(Rs. in

Millions)

i) From Directors

5.581

4.115

ii) From  Shareholders

0.479

0.404

Total

6.060

4.519

 

 

 

Banking Relations :

--

 

 

Auditors :

 

Name :

T. Rama Rao and Company

Chartered Accountants

Address :

303, Lotus House, 33A, New Marine Lines, Mumbai – 400 020, Maharashtra, India

Tel. No.:

91-22-22033725/ 22084904/ 22002868

Fax No.:

91-22-22054823

E-Mail :

tramarao@mtnl.net.in

turage_r@rediffmail.com

info@tramarao.com

PAN.:

AADPR8355E

 

 

CAPITAL STRUCTURE

 

As on 31.03.2011

 

Authorised Capital :

No. of Shares

Type

Value

Amount

500000

Equity Shares

Rs.10/- each

Rs.5.000 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

200000

Equity Shares

Rs.10/- each

Rs.2.000 Millions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2011

31.03.2010

31.03.2009

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

2.000

2.000

2.000

2] Share Application Money

0.000

0.000

0.000

3] Reserves & Surplus

46.061

41.800

33.646

4] (Accumulated Losses)

0.000

0.000

0.000

NETWORTH

48.061

43.800

35.646

LOAN FUNDS

 

 

 

1] Secured Loans

30.072

29.767

16.409

2] Unsecured Loans

6.060

4.519

2.030

TOTAL BORROWING

36.132

34.286

18.439

DEFERRED TAX LIABILITIES

3.062

3.445

0.967

 

 

 

 

TOTAL

87.255

81.531

55.052

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

48.880

50.776

26.359

Capital work-in-progress

0.000

0.000

0.000

 

 

 

 

INVESTMENT

2.196

1.740

2.619

DEFERREX TAX ASSETS

0.000

0.000

0.000

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

19.476
12.161

11.544

 

Sundry Debtors

29.400
22.567

22.119

 

Cash & Bank Balances

18.523
18.644

12.329

 

Other Current Assets

0.645
0.644

0.633

 

Loans & Advances

8.273
13.169

13.642

Total Current Assets

76.317

67.185

60.267

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Sundry Creditors

35.988
27.779

21.221

 

Other Current Liabilities

0.000
0.000

0.000

 

Provisions

4.150
10.391

12.972

Total Current Liabilities

40.138

38.170

34.193

Net Current Assets

36.179
29.015

26.074

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.000

0.000

 

 

 

 

TOTAL

87.255

81.531

55.052

 

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2011

31.03.2010

31.03.2009

 

SALES

 

 

 

Income

168.540

137.253

144.623

 

 

Other Income

 

 

 

 

 

TOTAL                                     (A)

168.540

137.253

144.623

 

 

 

 

 

 

EXPENSES

 

 

 

 

 

Operational Expenses

 

84.876

89.725

 

 

Administrative & Selling Expenses

 

30.108

25.503

 

 

TOTAL                                     (B)

150.588

114.984

115.228

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)      (C)

17.952

22.269

29.395

 

 

 

 

 

Less

FINANCIAL EXPENSES                         (D)

4.407

3.481

2.450

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

13.545

18.788

26.945

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

6.721

5.772

2.988

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                               (G)

6.824

13.016

23.957

 

 

 

 

 

Less

TAX                                                                  (H)

2.087

4.372

8.538

 

 

 

 

 

 

PROFIT AFTER TAX (G-H)                                (I)

4.737

8.644

15.419

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

38.842

30.981

16.107

 

 

 

 

 

Less

APPROPRIATIONS

 

 

 

 

 

Transfer to General Reserve

0.255

0.432

0.352

 

 

Tax on Dividend

0.351

0.351

0.500

 

BALANCE CARRIED TO THE B/S

42.973

38.842

30.981

 

 

 

 

 

 

Earnings Per Share (Rs.)

25.53

43.22

NA

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2011

31.03.2010

31.03.2009

PAT / Total Income

(%)

2.81
6.30

10.66

 

 

 
 

 

Return on Total Assets

(PBT/Total Assets}

(%)

5.45
11.03

27.66

 

 

 
 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.14
0.30

0.67

 

 

 
 

 

Debt Equity Ratio

(Total Liability/Networth)

 

1.59
1.65

1.48

 

 

 
 

 

Current Ratio

(Current Asset/Current Liability)

 

1.90
1.76

1.76

 

LOCAL AGENCY FURTHER INFORMATION

 

FORM 8

 

Corporate identity number of the company

U24110MH1996PTC102255

Name of the company

SRIKEM LABORATORIES PRIVATE LIMITED

Address of the registered office or of the principal place of  business in India of the company

Flat No.8, 2nd Floor, Laxmi Bhavan, Plot No.172-A, Jain Society, Sion (West), Mumbai – 400 022, Maharashtra, India

E-Mail: srikem@vsnl.com

This form is for

Modification of charge

Charge identification (ID) number of the charge to be modified

10006974

Type of charge

  • Book Debts
  • Movable Property
  • Floating Charge

Particular of charge holder

Oriental Bank of Commerce, “Meendeep” Ground Floor, 175, Gujarat Society, Sion (West), Mumbai – 400 022, Maharashtra, India

E-Mail: vlaxman@vsnl.com

Nature of instrument creating charge

a) Supplemental Agreement to secure Credit / Loan Facilities ; and

 

b) Common Agreement.

(Collectively constitute a single charge for Rs.57.500 millions).

Date of instrument Creating the charge

25.03.2011

Amount secured by the charge

Rs.57.500 Millions

Brief of the principal terms an conditions and extent and operation of the charge

Rate of Interest

Interest @ 12% p.a.

 

Terms of Repayment

Working facilities shall be repayable On demand ; and]

 

Term Loan shall be repayable in suitable installments.

 

Margin

As may be stipulated by Bank from time to time.

 

Extent and Operation of the charge

Hypothecation by way of First Charge on Company's Assets to secure a continuing security as mentioned in Column No.15 below for the repayment of Rs.57.500 millions together with interest, costs, charges, expenses and other moneys due and payable by the Company to the Bank.

Short particulars of the property or asset(s) charged (including complete address and location of the property)

Hypothecation of stocks of raw materials, SIP, Finished Goods of drugs, spares and stores, receivables, Plant & Machinery existing as well as  to be purchased.

Date of instrument modifying the charge

25.11.2009

Particulars of the present modification

The Bank having at the request of Company has agreed to sanction Additional Credit Facility of Rs.7.500 millions, thereby increasing the overall charge from Rs.50.000 millions to Rs.57.500 millions.

 

FIXED ASSETS:

 

  • Land including revalued
  • Factory Building
  • Plant and Machinery
  • Plant Tools and Equipments
  • Office Equipment
  • Computers
  • Motor Car
  • Laboratory Equipments
  • Electrical Fittings
  • Furniture and Fixtures
  • Motor Cycle
  • Wind Mill

 

WEBSITE DETAILS:

 

PROFILE:

 

They are a Mumbai (Bombay, India) based bulk drug and pharmaceutical actives manufacturing firm. The manufacturing unit is located just 50 kilometres from Mumbai which is well-connected to seaport and airports.

 

The unit is over 15 years old and it is owned and managed by a technocrat and first generation entrepreneur with over 25 years of experience having exposure to manufacturing products of international norms and quality standards. The plant is a multi-purpose unit handling many unit operations involved in organic synthesis, meeting the standards prescribed by various agencies like FDA, Pollution Control Board, Health and Safety Authorities.

 

They are approved vendors for the top 10 pharmaceutical companies in India. The products are accepted globally through direct and merchant exporters.

 

Future Plans

 

World-over, in all industries, tremendous changes are taking place due to newer technologies emerging. The pharma sector will be no exception to this trend

 

They, at subject, are gearing up to face the challenges for the future. They plan to foray into Anti-Fungal and Anti-bacterial sectors. They also have the facilities and the capacities to manufacture products and provide services on custom/toll manufacturing basis. They believe there is great scope in this sector for exploitation. Besides they have recently expanded the production capacity to meet the growing market needs for the products.

 

They are working towards approval of the facilities by International Regulatory agencies and accordingly they have upgraded the Plant and Machinery, Systems, Processes and Procedures to meet ICH Q7 Guidelines.

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                              None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.50.31

UK Pound

1

Rs.79.05

Euro

1

Rs.65.83

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

6

PAID-UP CAPITAL

1~10

5

OPERATING SCALE

1~10

5

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

5

--PROFITABILIRY

1~10

6

--LIQUIDITY

1~10

5

--LEVERAGE

1~10

5

--RESERVES

1~10

6

--CREDIT LINES

1~10

5

--MARGINS

-5~5

-

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

NO

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

48

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

-

NB

                                       New Business

-

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.